Reminder that BMY combo trial is looking at chemo combo ONLY in PD-L1 non-expressors, which they estimate is 30% of population. MRK & ROG.VX are looking at chemo combos in broad population.
Curious what makes you think Opdivo + Yervoy is a long shot, I thought the Phase 1 data from ASCO were extremely impressive?
Market Data 
Markets 
AI
